CliffBio

Blueprint Medicines

Patent cliffs & loss of exclusivity

Blueprint Medicines is a Cambridge, Massachusetts-based biotechnology company developing kinase inhibitors for systemic mastocytosis, other mast cell-driven diseases and cancer. Its approved medicine AYVAKIT (avapritinib) treats systemic mastocytosis and certain gastrointestinal stromal tumors. Sanofi acquired the company in July 2025.

Company

AngelList URLhttps://angel.co/blueprint-medicines
CAGE Code6NX60
Legal NameBlueprint Medicines Corporation
Company Operating StatusAcquired
Crunchbase URLhttps://www.crunchbase.com/organization/blueprint-medicines
Email format{f}{last}
Facebook URLhttps://www.facebook.com/pages/Blueprint-Medicines/1379814272250150
Full AddressBaarerstrasse 8 6300 Zug Switzerland

5 upcoming patent cliffs

DrugIngredientTypeCliff
  1. AYVAKITAVAPRITINIBSmall mol.Apr 2040
  2. AYVAKITAVAPRITINIBSmall mol.Apr 2040
  3. AYVAKITAVAPRITINIBSmall mol.Mar 2042
  4. AYVAKITAVAPRITINIBSmall mol.Mar 2042
  5. AYVAKITAVAPRITINIBSmall mol.Mar 2042

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.